Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 631 of 5804
-
Can early MS patients pause treatment? new trial seeks answers
Disease control Recruiting nowThis study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusi…
Phase: PHASE4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New eczema drug shows promise for people with darker skin
Disease control CompletedThe main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThe purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Gene therapy zolgensma tested in kids with SMA who stopped other drugs
Disease control CompletedThis was a Phase IIIb open-label, single arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101B in participants with SMA aged 2 to \<18 years after the discontinuation of treatment with nusinersen or risdiplam. The study aimed to enroll approximately…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Eczema drug dupilumab shows promise in skin of color patients
Disease control CompletedThe study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that th…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Precision dosing could make stem cell transplants safer for Non-Cancer patients
Disease control Recruiting nowAlemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogene…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising new combo aims to improve lung cancer treatment
Disease control OngoingThis study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squam…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
App aims to help pregnant women kick the habit
Disease control Recruiting nowThe objectives of this project are to develop, implement, and test the feasibility and effectiveness of an artificial intelligence adaptive mobile pregnancy tobacco cessation app-based intervention using deep tailoring and a self-nominated support person, and to build mHealth res…
Phase: NA • Sponsor: Michigan State University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for Long-Term control of IBD
Disease control OngoingThe primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD). Secondary objectives of the study are to: * evalu…
Phase: PHASE2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo aims to boost immune cells after lung cancer therapy
Disease control Recruiting nowTo learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Blood test may replace scans for heart attack staging
Diagnosis CompletedTROP-MI-STAGE is a multicenter retrospective diagnostic study designed to evaluate the role of high-sensitivity cardiac troponin I (hs-cTnI) in the diagnosis and clinical stage classification of acute myocardial infarction as defined by the stages of myocardial injury in CCS-AMI …
Sponsor: Rohan Dharmakumar • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Heart failure patients get a tiny shunt without a permanent implant
Disease control ENROLLING_BY_INVITATIONProspective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.
Phase: NA • Sponsor: Alleviant Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Your genes may determine if the Morning-After pill works
Disease control Recruiting nowThe purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.
Phase: PHASE4 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug aims to stop Flare-Ups in rare autoimmune disease
Disease control OngoingThis study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
Phase: PHASE3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug duo takes on tough cancers: hope for advanced bladder, kidney, and melanoma patients
Disease control OngoingThe objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced or Metastatic Urothelial Carcinoma (UC), Renal Cel…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy hopes to tackle tough bile duct cancer
Disease control Recruiting nowExplore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
Phase: PHASE2, PHASE3 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could your own fat heal Crohn's fistulas and prevent a colostomy bag?
Disease control Ongoingmulticentre randomized controlled prospective study aimed at evaluating the efficacy of the infiltration of microfractured adipose tissue in the healing of perianal fistulas not-responding to treatment with biologics, in order to improve the quality of life and significantly redu…
Phase: NA • Sponsor: Lipogems International spa • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could new tech replace the puffer test for asthma?
Diagnosis Recruiting nowThis trial aims to evaluate novel diagnostic technologies for asthma in 3 different pathways providing the necessary evidence-base to allow adoption into clinical practice: * Pathway 1 evaluates whether the technology can distinguish between people with asthma and healthy volunt…
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
New device aims to suck out dangerous blood clots, sparing patients from Long-Term leg damage
Disease control Recruiting nowThis study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conse…
Phase: NA • Sponsor: Inari Medical • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC